Contrasting demographic processes underlie uphill shifts in a desert ecosystem.

Climate change is projected to cause extensive plant range shifts, and, in many cases such shifts already are underway. Most long-term studies of range shifts measure emergent changes in species distributions but not the underlying demographic patterns that shape them. To better understand species' elevational range shifts and their underlying demographic processes, we use the powerful approach of rephotography, comparing historical (1978-1982) and modern (2015-2016) photographs taken along a 1000-m elevational gradient in the Colorado Desert of Southern California.

Beyond reporting: proactive strategies for safer scientific fieldwork.

Fieldwork is crucial for science but poses heightened risks of gender-based harassment and assault. Current practices prioritize post-incident reporting, despite the demonstrated potential of preventive approaches. We recommend proactive practices, training strategies, and systemic policy changes to build safe and inclusive fieldwork settings from the outset.

Testing the effectiveness of interactive training on sexual harassment and assault in field science.

Fieldwork is a critical tool for scientific research, particularly in applied disciplines. Yet fieldwork is often unsafe, especially for members of historically marginalized groups and people whose presence in scientific spaces threatens traditional hierarchies of power, authority, and legitimacy. Research is needed to identify interventions that prevent sexual harassment and assault from occurring in the first place.

Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report.

Vericiguat has emerged as a promising add-on therapy for decompensated heart failure with reduced ejection fraction (HFrEF) patients requiring hospitalization or IV diuretic administration. In the VICTORIA trial (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), vericiguat was demonstrated to significantly reduce mortality and hospitalization rates. However, the effect of vericiguat on patients receiving SGLT2 inhibitors remains uncertain.